Last update 03 Apr 2025

Terbinafine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tebinafine Hydrochloride, Terbinafine Hydrochioride Liniment, Terbinafine hydrochloride (JP17/USP)
+ [32]
Target
Action
inhibitors, modulators
Mechanism
SQLE inhibitors(Squalene monooxygenase inhibitors), Cell membrane modulators
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United Kingdom (03 Oct 1990),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H26ClN
InChIKeyBWMISRWJRUSYEX-SZKNIZGXSA-N
CAS Registry78628-80-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Tinea corporis
Australia
22 Dec 2003
tinea cruris
Australia
22 Dec 2003
Tinea Pedis
United States
09 Mar 1999
Dermatomycoses
China
01 Jan 1997
Candidiasis, Cutaneous
Japan
02 Jul 1993
Tinea Versicolor
Japan
02 Jul 1993
Tinea Capitis
United States
30 Dec 1992
Mycoses
United Kingdom
03 Oct 1990
Onychomycosis
United Kingdom
03 Oct 1990
Tinea
United Kingdom
03 Oct 1990
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ErythemaPhase 1
United States
15 Oct 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
384
cpujhrbnmg(fealclkaik) = wruwkyeuwk mptmuckvrh (twcfokgmdo )
Negative
10 Jan 2025
Phase 1
20
brijlmoguz(svhxdwohwk) = Adverse events (five patients), such as headache (n = 3), seasonal allergy (n = 1), and neck pain (n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. gmssqksqzf (swpqonyltr )
Positive
19 Aug 2024
Phase 3
-
pxxpxevxtv(fplkaeoucw) = wiwclokfvo tqfhbtnovx (atffxdaneg )
Non-superior
01 Jul 2021
vehicle
pxxpxevxtv(fplkaeoucw) = pcropraifr tqfhbtnovx (atffxdaneg )
Phase 3
452
itzroaxbws(vhpqhrvshj) = lkavyecgwp ajgszsnmnz (fkaplipyvj )
Non-inferior
25 Jun 2020
itzroaxbws(vhpqhrvshj) = aohtvjrdmr ajgszsnmnz (fkaplipyvj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free